Global Preclinical CRO Market Research Report Forecast to 2024

Array
(
    [id] => 1776373
    [discount] => PDF-18-ENTERPRISE WIDE LICENCE-20------
    [isbn] => 
    [title] => Global Preclinical CRO Market Research Report Forecast to 2024
    [upcommingtext] => 
    [seo_url] => global-preclinical-cro-market-research-report-forecast
    [shortdesc] => 
    [meta_title] => Global Preclinical CRO Market Research Report Forecast to 2024
    [keyword] => Global Preclinical CRO Market Research Report Forecast to 2024
    [description] => Global Preclinical CRO Market: Information by Service (Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies, Others), Application (Oncology, Central Nervous System (CNS) Disorders, Cardiovascular Diseases, Immunological Disorders, Respiratory
    [curr] => USD
    [category] => 1236
    [publisher] => 182
    [published_date] => 2019-07-30
    [country] => 230
    [author_name] => 
    [page_num] => 125
    [abstract] => Global Preclinical CRO Market: Information by Service (Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies, Others), Application (Oncology, Central Nervous System (CNS) Disorders, Cardiovascular Diseases, Immunological Disorders, Respiratory Diseases, Infectious Diseases, Diabetes and Others), by End User (Pharmaceutical and Biopharmaceutical Industries, Medical Device Companies and Academic Institutes) and Region - Forecast till 2024

Market Analysis
A preclinical CRO distributes the practice, information and ability that is required to take a therapeutic product or a medical device from its clinical stage to advertising or delivery. Benefitting the growth in subcontracting of non-core purposes, improved abilities of preclinical CROs, the global preclinical CRO market has been principally helped to offer supplementary value-added services, rolling number of drugs in the preclinical phase, economies of production & scale, mutual advantage to the contractor as well as the client and high R&D expenditure. However, its has been noted that the shortage of labor as well as high labor cost, operational variations in the industry is predicted to confine the market growth. The global market for preclinical CRO is expected to drive owing to aspects for example development in outsourcing of non-core functions, boosted abilities of preclinical CROs to offer additional value-added services and heaving number of drugs in preclinical stages. Furthermore, economies of production and scale is a shared advantage to the outworker as well as the client and high R&D outflow are expected to fund the growth of the market in the coming years.

Market segmentation
The collective urge for experimenting new drugs and chemicals as well as dynamic progress in the pharmaceutical and biopharmaceutical segments are expected to drive the market. However, the bioanalysis and drug metabolism and pharmacokinetics (DMPK) studies section is likely to parade the highest CAGR of 8.96% from 2019 to 2024. Innovative technological advances by various companies to deliver healthier services to pharmaceutical companies and is driving the growth of the sector simultaneously. The Key players in the market segmented, can be given by service (i.e. Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies and others), By Application (Immunological Disorders, Respiratory Diseases, Oncology, Diabetes, Cardiovascular Diseases, Infectious Diseases and others), By End User (Medical Device Companies, Academic Institutes, Pharmaceutical and Biopharmaceutical Industries and others), By Region (North America, Europe, Asia-Pacific and Rest of the World).The SWOT Analysis of the Global Preclinical CRO Market can be further customized and can be available as an additional article into the main report. The toxicological testing segment is projected to head the market and roll a substantial CAGR to reach USD 2,476.28 Million by the end of 2024.
Regional analysis
Geographically, the Global Preclinical CRO Market is segmented and targeted into global regions like North America, Asia-Pacific, Middle East and Africa along with the European market. The European market is projected to surpass USD 1,670.19 Million by 2024. The cumulative farm out activities in Europe, low labor cost & engineering cost and accessibility of expert medical force are the reasons driving the growth of the preclinical CRO market in the region. Americas considered to be the largest market share of 40.7% in 2018, and the regional market is projected to list a CAGR of 7.49% throughout the prediction period. Asia-Pacific is expected to register the fastest CAGR. The Indian market is probable to show the uppermost growth rate of 9.44% during the forecast period of 2019 to 2024.


Major players
The bulging players in the Global Preclinical CRO Market. Are compnaies like Pharmaceutical Product Development, LLC (US), MD Biosciences (US)., IQVIA (US), PAREXEL International Corporation (US), Envigo (US), Charles River (US), ICON PLC (Dublin), PRA Health Sciences (US), Medpace (US), Laboratory Corporation of America Holdings (US), WuXi AppTec (China) and Eurofins Scientific (Luxembourg. The players operating in the global preclinical CRO market are focusing on product unveilings, along with intensifying their global footpaths by entering untouched markets. [table_of_contents] =>

1 Executive Summary
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Overview
4.2 Drivers
4.2.1 Growth in Outsourcing of Non-Core Functions
4.2.2 Enhanced Abilities of Preclinical CROs to Offer Additional Value-Added Services
4.2.3 Surging Number of Drugs in the Preclinical Phase
4.2.4 Economies of Production and Scale
4.2.5 Mutual Benefit to the Contractor as Well as the Client
4.2.6 High R&D Expenditure
4.3 Restraints
4.3.1 Scarcity of Labour and High Labour Cost
4.3.2 Structural Changes in the Industry
4.4 Opportunity
4.4.1 Opportunity for Medical Device Companies to Outsource Preclinical Trials to CROs
4.5 Challenges
4.5.1 Supply Chain Complexity and Third-Party Control
4.5.2 Outdated Clinical Trial Activities
4.6 Macroeconomic Indicators
4.7 Trends
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 R&D
5.1.2 Good Laboratory Practices (GLP)
5.1.3 Pre-Clinical CRO Testing
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitutes
5.2.5 Intensity of Rivalry
5.3 Investment Opportunities
5.4 Pricing Analysis
6 Global Preclinical CRO Market, By Service
6.1 Overview
6.2 Toxicology Testing
6.3 Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
6.4 Others
7 Global Preclinical CRO Market, By Therapeutic Area
7.1 Overview
7.2 Oncology
7.3 Central Nervous System (CNS) Disorders
7.4 Cardiovascular Diseases
7.5 Immunological Disorders
7.6 Respiratory Diseases
7.7 Infectious Diseases
7.8 Diabetes
7.9 Others
8 Global Preclinical CRO Market, By End User
8.1 Overview
8.2 Pharmaceutical and Biopharmaceutical Industries
8.3 Medical Device Companies
8.4 Academic Institutes
9 Global Preclinical CRO Market, By Region
9.1 Overview
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 Latin America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 UK
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
10 Competitive Landscape
10.1 Introduction
10.2 Company Share Analysis
11 Company Profile
11.1 IQVIA
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products/Services Offered
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategies
11.2 PAREXEL International Corporation
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products Offering
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategies
11.3 Envigo
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products Offering
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategies
11.4 Charles River
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products/Services Offered
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategies
11.5 Eurofins Scientific
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products/Services Offered
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategies
11.6 ICON PLC
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products/Services Offered
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategies
11.7 PRA Health Sciences (PRA)
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products/Services Offered
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategies
11.8 Medpace
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products/Services Offered
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategies
11.9 Laboratory Corporation of America Holdings
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products/Services Offered
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategies
11.1 Pharmaceutical Product Development, LLC
11.10.1 Company Overview
11.10.2 Financial Overview
11.10.3 Products/Services Offered
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key Strategies
11.11 WuXi AppTec
11.11.1 Company Overview
11.11.2 Financial Overview
11.11.3 Products/Services Offered
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.11.6 Key Strategies
11.12 MD Biosciences
11.12.1 Company Overview
11.12.2 Financial Overview
11.12.3 Products/Services Offered
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.12.6 Key Strategies
12 Appendix
12.1 References
12.2 Related Reports [list_of_tables] =>

TABLE 1 GLOBAL PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 2 GLOBAL PRECLINICAL CRO MARKET, FOR TOXICOLOGY TESTING, BY REGION, 2016–2024 (USD MILLION)
TABLE 3 GLOBAL PRECLINICAL CRO MARKET, FOR BIOANALYSIS AND DRUG METABOLISM AND PHARMACOKINETICS (DMPK) STUDIES, BY REGION, 2016–2024 (USD MILLION)
TABLE 4 GLOBAL PRECLINICAL CRO MARKET, FOR OTHERS, BY REGION, 2016–2024 (USD MILLION)
TABLE 5 GLOBAL PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 6 GLOBAL PRECLINICAL CRO MARKET, FOR ONCOLOGY, BY REGION, 2016–2024 (USD MILLION)
TABLE 7 GLOBAL PRECLINICAL CRO MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, BY REGION, 2016–2024 (USD MILLION)
TABLE 8 GLOBAL PRECLINICAL CRO MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2016–2024 (USD MILLION)
TABLE 9 GLOBAL PRECLINICAL CRO MARKET, FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2016–2024 (USD MILLION)
TABLE 10 GLOBAL PRECLINICAL CRO MARKET, FOR RESPIRATORY DISEASES, BY REGION, 2016–2024 (USD MILLION)
TABLE 11 GLOBAL PRECLINICAL CRO MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2016–2024 (USD MILLION)
TABLE 12 GLOBAL PRECLINICAL CRO MARKET, FOR DIABETES, BY REGION, 2016–2024 (USD MILLION)
TABLE 13 GLOBAL PRECLINICAL CRO MARKET, FOR OTHERS, BY REGION, 2016–2024 (USD MILLION)
TABLE 14 GLOBAL PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 15 GLOBAL PRECLINICAL CRO MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRIES, BY REGION, 2016–2024 (USD MILLION)
TABLE 16 GLOBAL PRECLINICAL CRO MARKET, FOR MEDICAL DEVICE COMPANIES, BY REGION, 2016–2024 (USD MILLION)
TABLE 17 GLOBAL PRECLINICAL CRO MARKET, FOR ACADEMIC INSTITUTES, BY REGION, 2016–2024 (USD MILLION)
TABLE 18 GLOBAL PRECLINICAL CRO MARKET, BY REGION, 2016–2024 (USD MILLION)
TABLE 19 GLOBAL PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
TABLE 20 GLOBAL PRECLINICAL CRO MARKET, BY REGION, 2018 & 2024 (USD MILLION)
TABLE 21 AMERICAS: PRECLINICAL CRO MARKET, BY REGION, 2016–2024 (USD MILLION)
TABLE 22 AMERICAS: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 23 AMERICAS: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 24 AMERICAS: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 25 NORTH AMERICA: PRECLINICAL CRO MARKET, BY COUNTRY, 2016–2024 (USD MILLION)
TABLE 26 NORTH AMERICA: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 27 NORTH AMERICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 28 NORTH AMERICA: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 29 US: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 30 US: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 31 US: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 32 CANADA: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 33 CANADA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 34 CANADA: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 35 LATIN AMERICA: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 36 LATIN AMERICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 37 LATIN AMERICA: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 38 EUROPE: PRECLINICAL CRO MARKET, BY REGION, 2016–2024 (USD MILLION)
TABLE 39 EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 40 EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 41 EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 42 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY COUNTRY, 2016–2024 (USD MILLION)
TABLE 43 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 44 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 45 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 46 GERMANY: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 47 GERMANY: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 48 GERMANY: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 49 FRANCE: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 50 FRANCE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 51 FRANCE: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 52 UK: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 53 UK: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 54 UK: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 55 ITALY: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 56 ITALY: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 57 ITALY: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 58 SPAIN: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 59 SPAIN: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 60 SPAIN: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 61 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 62 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 63 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 64 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 65 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 66 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 67 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY COUNTRY, 2016–2024 (USD MILLION)
TABLE 68 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 69 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 70 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 71 JAPAN: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 72 JAPAN: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 73 JAPAN: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 74 CHINA: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 75 CHINA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 76 CHINA: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 77 INDIA: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 78 INDIA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 79 INDIA: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 80 AUSTRALIA: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 81 AUSTRALIA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 82 AUSTRALIA: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 83 SOUTH KOREA: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 84 SOUTH KOREA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 85 SOUTH KOREA: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 86 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 87 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 88 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 89 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY REGION, 2016–2024 (USD MILLION)
TABLE 90 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 91 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 92 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 93 MIDDLE EAST: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 94 MIDDLE EAST: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 95 MIDDLE EAST: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 96 AFRICA: PRECLINICAL CRO MARKET, BY SERVICE, 2016–2024 (USD MILLION)
TABLE 97 AFRICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2016–2024 (USD MILLION)
TABLE 98 AFRICA: PRECLINICAL CRO MARKET, BY END USER, 2016–2024 (USD MILLION)
TABLE 99 KEY DEVELOPMENTS & STRATEGIES [list_of_figures] =>

FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL PRECLINICAL CRO MARKET: MARKET STRUCTURE
FIGURE 3 RESEARCH PROCESS OF MRFR
FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 5 MARKET DYNAMICS: GLOBAL PRECLINICAL CRO MARKET
FIGURE 6 VALUE CHAIN: GLOBAL PRECLINICAL CRO MARKET
FIGURE 7 PORTER’S FIVE FORCES ANALYSIS: GLOBAL PRECLINICAL CRO MARKET
FIGURE 8 GLOBAL PRECLINICAL CRO MARKET SHARE, BY SERVICE, 2018 (%)
FIGURE 9 GLOBAL PRECLINICAL CRO MARKET, BY SERVICE, 2018 & 2024 (USD MILLION)
FIGURE 10 GLOBAL PRECLINICAL CRO MARKET SHARE, BY THERAPEUTIC AREA, 2018 (%)
FIGURE 11 GLOBAL PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2018 & 2024 (USD MILLION)
FIGURE 12 GLOBAL PRECLINICAL CRO MARKET SHARE, BY END USER, 2018 (%)
FIGURE 13 GLOBAL PRECLINICAL CRO MARKET, BY END USER, 2018 & 2024 (USD MILLION)
FIGURE 14 AMERICAS: PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
FIGURE 15 NORTH AMERICA: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 16 EUROPE: PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
FIGURE 17 WESTERN EUROPE: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 18 ASIA-PACIFIC: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 19 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
FIGURE 20 GLOBAL PRECLINICAL CRO MARKET SHARE ANALYSIS 2017 (%) [sample_page] => [brochure] => [new_price] => PDF-4450-ENTERPRISE WIDE LICENCE-6250-GLOBAL LICENCE--MULTI USER LICENCE--GLOBAL SITE LICENCE--Enterprise Wide Licence--Multi User Licence- )
discount aarkstore
Global Preclinical CRO Market: Information by Service (Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies, Others), Application (Oncology, Central Nervous System (CNS) Disorders, Cardiovascular Diseases, Immunological Disorders, Respiratory Diseases, Infectious Diseases, Diabetes and Others), by End User (Pharmaceutical and Biopharmaceutical Industries, Medical Device Companies and Academic Institutes) and Region - Forecast till 2024

Market Analysis
A preclinical CRO distributes the practice, information and ability that is required to take a therapeutic product or a medical device from its clinical stage to advertising or delivery. Benefitting the growth in subcontracting of non-core purposes, improved abilities of preclinical CROs, the global preclinical CRO market has been principally helped to offer supplementary value-added services, rolling number of drugs in the preclinical phase, economies of production & scale, mutual advantage to the contractor as well as the client and high R&D expenditure. However, its has been noted that the shortage of labor as well as high labor cost, operational variations in the industry is predicted to confine the market growth. The global market for preclinical CRO is expected to drive owing to aspects for example development in outsourcing of non-core functions, boosted abilities of preclinical CROs to offer additional value-added services and heaving number of drugs in preclinical stages. Furthermore, economies of production and scale is a shared advantage to the outworker as well as the client and high R&D outflow are expected to fund the growth of the market in the coming years.

Market segmentation
The collective urge for experimenting new drugs and chemicals as well as dynamic progress in the pharmaceutical and biopharmaceutical segments are expected to drive the market. However, the bioanalysis and drug metabolism and pharmacokinetics (DMPK) studies section is likely to parade the highest CAGR of 8.96% from 2019 to 2024. Innovative technological advances by various companies to deliver healthier services to pharmaceutical companies and is driving the growth of the sector simultaneously. The Key players in the market segmented, can be given by service (i.e. Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies and others), By Application (Immunological Disorders, Respiratory Diseases, Oncology, Diabetes, Cardiovascular Diseases, Infectious Diseases and others), By End User (Medical Device Companies, Academic Institutes, Pharmaceutical and Biopharmaceutical Industries and others), By Region (North America, Europe, Asia-Pacific and Rest of the World).The SWOT Analysis of the Global Preclinical CRO Market can be further customized and can be available as an additional article into the main report. The toxicological testing segment is projected to head the market and roll a substantial CAGR to reach USD 2,476.28 Million by the end of 2024.
Regional analysis
Geographically, the Global Preclinical CRO Market is segmented and targeted into global regions like North America, Asia-Pacific, Middle East and Africa along with the European market. The European market is projected to surpass USD 1,670.19 Million by 2024. The cumulative farm out activities in Europe, low labor cost & engineering cost and accessibility of expert medical force are the reasons driving the growth of the preclinical CRO market in the region. Americas considered to be the largest market share of 40.7% in 2018, and the regional market is projected to list a CAGR of 7.49% throughout the prediction period. Asia-Pacific is expected to register the fastest CAGR. The Indian market is probable to show the uppermost growth rate of 9.44% during the forecast period of 2019 to 2024.


Major players
The bulging players in the Global Preclinical CRO Market. Are compnaies like Pharmaceutical Product Development, LLC (US), MD Biosciences (US)., IQVIA (US), PAREXEL International Corporation (US), Envigo (US), Charles River (US), ICON PLC (Dublin), PRA Health Sciences (US), Medpace (US), Laboratory Corporation of America Holdings (US), WuXi AppTec (China) and Eurofins Scientific (Luxembourg. The players operating in the global preclinical CRO market are focusing on product unveilings, along with intensifying their global footpaths by entering untouched markets.


1Executive Summary
2Market Introduction
2.1Definition
2.2Scope of the Study
2.3Market Structure
3Research Methodology
3.1Research Process
3.2Primary Research
3.3Secondary Research
3.4Market Size Estimation
3.5Forecast Model
4Market Dynamics
4.1Overview
4.2Drivers
4.2.1Growth in Outsourcing of Non-Core Functions
4.2.2Enhanced Abilities of Preclinical CROs to Offer Additional Value-Added Services
4.2.3Surging Number of Drugs in the Preclinical Phase
4.2.4Economies of Production and Scale
4.2.5Mutual Benefit to the Contractor as Well as the Client
4.2.6High R&D Expenditure
4.3Restraints
4.3.1Scarcity of Labour and High Labour Cost
4.3.2Structural Changes in the Industry
4.4Opportunity
4.4.1Opportunity for Medical Device Companies to Outsource Preclinical Trials to CROs
4.5Challenges
4.5.1Supply Chain Complexity and Third-Party Control
4.5.2Outdated Clinical Trial Activities
4.6Macroeconomic Indicators
4.7Trends
5Market Factor Analysis
5.1Value Chain Analysis
5.1.1R&D
5.1.2Good Laboratory Practices (GLP)
5.1.3Pre-Clinical CRO Testing
5.2Porters Five Forces Analysis
5.2.1Bargaining Power of Suppliers
5.2.2Bargaining Power of Buyers
5.2.3Threat of New Entrants
5.2.4Threat of Substitutes
5.2.5Intensity of Rivalry
5.3Investment Opportunities
5.4Pricing Analysis
6Global Preclinical CRO Market, By Service
6.1Overview
6.2Toxicology Testing
6.3Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
6.4Others
7Global Preclinical CRO Market, By Therapeutic Area
7.1Overview
7.2Oncology
7.3Central Nervous System (CNS) Disorders
7.4Cardiovascular Diseases
7.5Immunological Disorders
7.6Respiratory Diseases
7.7Infectious Diseases
7.8Diabetes
7.9Others
8Global Preclinical CRO Market, By End User
8.1Overview
8.2Pharmaceutical and Biopharmaceutical Industries
8.3Medical Device Companies
8.4Academic Institutes
9Global Preclinical CRO Market, By Region
9.1Overview
9.2Americas
9.2.1North America
9.2.1.1US
9.2.1.2Canada
9.2.2Latin America
9.3Europe
9.3.1Western Europe
9.3.1.1Germany
9.3.1.2France
9.3.1.3UK
9.3.1.4Italy
9.3.1.5Spain
9.3.1.6Rest of Western Europe
9.3.2Eastern Europe
9.4Asia-Pacific
9.4.1Japan
9.4.2China
9.4.3India
9.4.4Australia
9.4.5South Korea
9.4.6Rest of Asia-Pacific
9.5Middle East & Africa
9.5.1Middle East
9.5.2Africa
10Competitive Landscape
10.1Introduction
10.2Company Share Analysis
11Company Profile
11.1IQVIA
11.1.1Company Overview
11.1.2Financial Overview
11.1.3Products/Services Offered
11.1.4Key Developments
11.1.5SWOT Analysis
11.1.6Key Strategies
11.2PAREXEL International Corporation
11.2.1Company Overview
11.2.2Financial Overview
11.2.3Products Offering
11.2.4Key Developments
11.2.5SWOT Analysis
11.2.6Key Strategies
11.3Envigo
11.3.1Company Overview
11.3.2Financial Overview
11.3.3Products Offering
11.3.4Key Developments
11.3.5SWOT Analysis
11.3.6Key Strategies
11.4Charles River
11.4.1Company Overview
11.4.2Financial Overview
11.4.3Products/Services Offered
11.4.4Key Developments
11.4.5SWOT Analysis
11.4.6Key Strategies
11.5Eurofins Scientific
11.5.1Company Overview
11.5.2Financial Overview
11.5.3Products/Services Offered
11.5.4Key Developments
11.5.5SWOT Analysis
11.5.6Key Strategies
11.6ICON PLC
11.6.1Company Overview
11.6.2Financial Overview
11.6.3Products/Services Offered
11.6.4Key Developments
11.6.5SWOT Analysis
11.6.6Key Strategies
11.7PRA Health Sciences (PRA)
11.7.1Company Overview
11.7.2Financial Overview
11.7.3Products/Services Offered
11.7.4Key Developments
11.7.5SWOT Analysis
11.7.6Key Strategies
11.8Medpace
11.8.1Company Overview
11.8.2Financial Overview
11.8.3Products/Services Offered
11.8.4Key Developments
11.8.5SWOT Analysis
11.8.6Key Strategies
11.9Laboratory Corporation of America Holdings
11.9.1Company Overview
11.9.2Financial Overview
11.9.3Products/Services Offered
11.9.4Key Developments
11.9.5SWOT Analysis
11.9.6Key Strategies
11.1Pharmaceutical Product Development, LLC
11.10.1Company Overview
11.10.2Financial Overview
11.10.3Products/Services Offered
11.10.4Key Developments
11.10.5SWOT Analysis
11.10.6Key Strategies
11.11WuXi AppTec
11.11.1Company Overview
11.11.2Financial Overview
11.11.3Products/Services Offered
11.11.4Key Developments
11.11.5SWOT Analysis
11.11.6Key Strategies
11.12MD Biosciences
11.12.1Company Overview
11.12.2Financial Overview
11.12.3Products/Services Offered
11.12.4Key Developments
11.12.5SWOT Analysis
11.12.6Key Strategies
12Appendix
12.1References
12.2Related Reports

List Of Tables



TABLE 1GLOBAL PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 2GLOBAL PRECLINICAL CRO MARKET, FOR TOXICOLOGY TESTING, BY REGION, 20162024 (USD MILLION)
TABLE 3GLOBAL PRECLINICAL CRO MARKET, FOR BIOANALYSIS AND DRUG METABOLISM AND PHARMACOKINETICS (DMPK) STUDIES, BY REGION, 20162024 (USD MILLION)
TABLE 4GLOBAL PRECLINICAL CRO MARKET, FOR OTHERS, BY REGION, 20162024 (USD MILLION)
TABLE 5GLOBAL PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 6GLOBAL PRECLINICAL CRO MARKET, FOR ONCOLOGY, BY REGION, 20162024 (USD MILLION)
TABLE 7GLOBAL PRECLINICAL CRO MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, BY REGION, 20162024 (USD MILLION)
TABLE 8GLOBAL PRECLINICAL CRO MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 20162024 (USD MILLION)
TABLE 9GLOBAL PRECLINICAL CRO MARKET, FOR IMMUNOLOGICAL DISORDERS, BY REGION, 20162024 (USD MILLION)
TABLE 10GLOBAL PRECLINICAL CRO MARKET, FOR RESPIRATORY DISEASES, BY REGION, 20162024 (USD MILLION)
TABLE 11GLOBAL PRECLINICAL CRO MARKET, FOR INFECTIOUS DISEASES, BY REGION, 20162024 (USD MILLION)
TABLE 12GLOBAL PRECLINICAL CRO MARKET, FOR DIABETES, BY REGION, 20162024 (USD MILLION)
TABLE 13GLOBAL PRECLINICAL CRO MARKET, FOR OTHERS, BY REGION, 20162024 (USD MILLION)
TABLE 14GLOBAL PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 15GLOBAL PRECLINICAL CRO MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRIES, BY REGION, 20162024 (USD MILLION)
TABLE 16GLOBAL PRECLINICAL CRO MARKET, FOR MEDICAL DEVICE COMPANIES, BY REGION, 20162024 (USD MILLION)
TABLE 17GLOBAL PRECLINICAL CRO MARKET, FOR ACADEMIC INSTITUTES, BY REGION, 20162024 (USD MILLION)
TABLE 18GLOBAL PRECLINICAL CRO MARKET, BY REGION, 20162024 (USD MILLION)
TABLE 19GLOBAL PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
TABLE 20GLOBAL PRECLINICAL CRO MARKET, BY REGION, 2018 & 2024 (USD MILLION)
TABLE 21AMERICAS: PRECLINICAL CRO MARKET, BY REGION, 20162024 (USD MILLION)
TABLE 22AMERICAS: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 23AMERICAS: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 24AMERICAS: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 25NORTH AMERICA: PRECLINICAL CRO MARKET, BY COUNTRY, 20162024 (USD MILLION)
TABLE 26NORTH AMERICA: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 27NORTH AMERICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 28NORTH AMERICA: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 29US: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 30US: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 31US: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 32CANADA: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 33CANADA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 34CANADA: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 35LATIN AMERICA: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 36LATIN AMERICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 37LATIN AMERICA: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 38EUROPE: PRECLINICAL CRO MARKET, BY REGION, 20162024 (USD MILLION)
TABLE 39EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 40EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 41EUROPE: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 42WESTERN EUROPE: PRECLINICAL CRO MARKET, BY COUNTRY, 20162024 (USD MILLION)
TABLE 43WESTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 44WESTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 45WESTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 46GERMANY: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 47GERMANY: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 48GERMANY: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 49FRANCE: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 50FRANCE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 51FRANCE: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 52UK: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 53UK: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 54UK: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 55ITALY: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 56ITALY: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 57ITALY: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 58SPAIN: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 59SPAIN: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 60SPAIN: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 61REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 62REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 63REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 64EASTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 65EASTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 66EASTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 67ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY COUNTRY, 20162024 (USD MILLION)
TABLE 68ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 69ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 70ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 71JAPAN: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 72JAPAN: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 73JAPAN: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 74CHINA: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 75CHINA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 76CHINA: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 77INDIA: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 78INDIA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 79INDIA: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 80AUSTRALIA: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 81AUSTRALIA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 82AUSTRALIA: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 83SOUTH KOREA: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 84SOUTH KOREA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 85SOUTH KOREA: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 86REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 87REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 88REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 89MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY REGION, 20162024 (USD MILLION)
TABLE 90MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 91MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 92MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 93MIDDLE EAST: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 94MIDDLE EAST: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 95MIDDLE EAST: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 96AFRICA: PRECLINICAL CRO MARKET, BY SERVICE, 20162024 (USD MILLION)
TABLE 97AFRICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 20162024 (USD MILLION)
TABLE 98AFRICA: PRECLINICAL CRO MARKET, BY END USER, 20162024 (USD MILLION)
TABLE 99KEY DEVELOPMENTS & STRATEGIES

List Of Figures



FIGURE 1MARKET SYNOPSIS
FIGURE 2GLOBAL PRECLINICAL CRO MARKET: MARKET STRUCTURE
FIGURE 3RESEARCH PROCESS OF MRFR
FIGURE 4TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 5MARKET DYNAMICS: GLOBAL PRECLINICAL CRO MARKET
FIGURE 6VALUE CHAIN: GLOBAL PRECLINICAL CRO MARKET
FIGURE 7PORTERS FIVE FORCES ANALYSIS: GLOBAL PRECLINICAL CRO MARKET
FIGURE 8GLOBAL PRECLINICAL CRO MARKET SHARE, BY SERVICE, 2018 (%)
FIGURE 9GLOBAL PRECLINICAL CRO MARKET, BY SERVICE, 2018 & 2024 (USD MILLION)
FIGURE 10GLOBAL PRECLINICAL CRO MARKET SHARE, BY THERAPEUTIC AREA, 2018 (%)
FIGURE 11GLOBAL PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2018 & 2024 (USD MILLION)
FIGURE 12GLOBAL PRECLINICAL CRO MARKET SHARE, BY END USER, 2018 (%)
FIGURE 13GLOBAL PRECLINICAL CRO MARKET, BY END USER, 2018 & 2024 (USD MILLION)
FIGURE 14AMERICAS: PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
FIGURE 15NORTH AMERICA: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 16EUROPE: PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
FIGURE 17WESTERN EUROPE: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 18ASIA-PACIFIC: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 19MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET SHARE, BY REGION, 2018 (%)
FIGURE 20GLOBAL PRECLINICAL CRO MARKET SHARE ANALYSIS 2017 (%)

Systemic Lupus Erythematosus and Lupus Nephritis: Global Drug Forecast and Market Analysis to 2027

Systemic Lupus Erythematosus and Lupus Nephritis: Global Drug Forecast and Market Analysis to 2027 market research report available in single user pdf license with Aarkstore Enterprise at USD 10995

USD 10995 View Report

Insulin Drugs Global Market Report 2020

Insulin Drugs Global Market Report 2020 market research report available in single user pdf license with Aarkstore Enterprise at USD 4000

USD 4000 View Report

Global Preclinical Imaging In Vivo Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Preclinical Imaging In Vivo is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by

USD 4000 View Report

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019

The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage

USD 2995 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available